Clinical impact in the real life of guidelines recommendations for atopic dermatitis in a tropical population (TECCEMA cohort)

ABSTRACT: Background: Real-life impact of guidelines for the management of atopic dermatitis has been poorly studied. Objective: To assess atopic dermatitis clinical control in residents of a tropical area managed according to international consensuses. Methods: Prospective study with a 24-month fol...

Full description

Autores:
Sánchez Caraballo, Jorge Mario
Toro Colorado, Yuliana
Cardona Villa, Ricardo
Tipo de recurso:
Article of investigation
Fecha de publicación:
2017
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/31179
Acceso en línea:
https://hdl.handle.net/10495/31179
Palabra clave:
Eccema
Eczema
Quimioterapia
Drug Therapy
Dermatitis Atópica
Dermatitis, Atopic
Calidad de Vida
Quality of Life
Dermatitis
Dermatitis por Contacto
Dermatitis, Contact
Guías de Práctica Clínica como Asunto
Practice Guidelines as Topic
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc/2.5/co/
Description
Summary:ABSTRACT: Background: Real-life impact of guidelines for the management of atopic dermatitis has been poorly studied. Objective: To assess atopic dermatitis clinical control in residents of a tropical area managed according to international consensuses. Methods: Prospective study with a 24-month follow-up. Clinical response was assessed with SCORAD, DLQI and a subjective scale (SS) on severity perception by the patient. Results: Two-hundred and thirty-three patients were stratified according to SCORAD: 53 had mild severity (22%), 116 moderate (49%) and 64 severe (27%). Baseline SCORAD mean was 33 (15-41), for DLQI, it was 14 (11-20), and for the subjective scale, 85% (67-99). At 6 months, there was significant reduction (p < 0.5): SCORAD 29 (14-41), DLQI 12 (8-16) and subjective scale 62% (45-80). At 2 years, SCORAD was 21 (9-34), DLQI 7 (4-10) and subjective scale 41% (27-56); only 33% achieved complete control (SCORAD < 15%, DLQI < 5, subjective scale < 20%). Conclusions: Following international guidelines’ recommendations reduces eczema severity and improves quality of life, although only 33% achieved complete control after 2 years.